Investigated for treating COVID-19.
Epoetin alfa-epbx (Retacrit) is biosimilar to Epoetin alfa (Epogen/Procrit). Approved 05/15/2018
- TRADE NAMES: Binocrit; Epogen (Amgen); Epoxitin; Eprex (Janssen-Cilag); Erypo; Procrit (Ortho)
- INDICATIONS: Anemia
- SYNONYM: erythropoietin; EPO
- CLASS: Erythropoiesis-stimulating agent (ESA), Erythropoietin
- HALF-LIFE: 4–13 hours (in patients with chronic renal failure)
- FDA APPROVAL DATE: 06/01/1989
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 06/04/2024
